Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin
INTRODUCTION: Sodium glucose cotransporter (SGLT) inhibitors may increase beta-hydroxybutyrate (BHB) in insulin-requiring patients. We determined factors associated with BHB changes from baseline (ΔBHB) and diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) receiving sotagliflozin as an insulin adjunct.
RESEARCH DESIGN AND METHODS: This post-hoc analysis compared ΔBHB levels in adults with T1D receiving sotagliflozin 400 mg or placebo for 6 months. We evaluated clinical and metabolic factors associated with ΔBHB and used logistic regression models to determine predictors associated with BHB values >0.6 and >1.5 mmol/L (inTandem3 population; N=1402) or with DKA events in a pooled analysis (inTandem1-3; N=2453).
RESULTS: From baseline (median, 0.13 mmol/L), median fasting BHB increased by 0.04 mmol/L (95% confidence interval, 0.03-0.05; P<0.001) at 24 weeks with sotagliflozin vs. placebo; 67% of patients had no or minimal changes in BHB over time. Factors associated with on-treatment BHB >0.6 or >1.5 mmol/L included baseline BHB and sotagliflozin use. Age, insulin pump use, sotagliflozin use, baseline BHB, and ΔBHB were significantly associated with DKA episodes. Independent of treatment, DKA risk increased by 18% with each 0.1-mmol/L increase in baseline BHB and by 8% with each 0.1-mmol/L increase from baseline.
CONCLUSION: Incremental increases in baseline BHB and ΔBHB were associated with higher DKA risk independent of treatment. Adding sotagliflozin to insulin increased median BHB over 24 weeks in patients with T1D and was associated with increased DKA events. These results highlight the importance of BHB testing and monitoring and individualizing patient education on DKA risk, mitigation, identification, and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Diabetes technology & therapeutics - (2024) vom: 05. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boeder, Schafer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1089/dia.2023.0605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369317599 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369317599 | ||
| 003 | DE-627 | ||
| 005 | 20240305233308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/dia.2023.0605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM369317599 | ||
| 035 | |a (NLM)38441906 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boeder, Schafer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a INTRODUCTION: Sodium glucose cotransporter (SGLT) inhibitors may increase beta-hydroxybutyrate (BHB) in insulin-requiring patients. We determined factors associated with BHB changes from baseline (ΔBHB) and diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) receiving sotagliflozin as an insulin adjunct | ||
| 520 | |a RESEARCH DESIGN AND METHODS: This post-hoc analysis compared ΔBHB levels in adults with T1D receiving sotagliflozin 400 mg or placebo for 6 months. We evaluated clinical and metabolic factors associated with ΔBHB and used logistic regression models to determine predictors associated with BHB values >0.6 and >1.5 mmol/L (inTandem3 population; N=1402) or with DKA events in a pooled analysis (inTandem1-3; N=2453) | ||
| 520 | |a RESULTS: From baseline (median, 0.13 mmol/L), median fasting BHB increased by 0.04 mmol/L (95% confidence interval, 0.03-0.05; P<0.001) at 24 weeks with sotagliflozin vs. placebo; 67% of patients had no or minimal changes in BHB over time. Factors associated with on-treatment BHB >0.6 or >1.5 mmol/L included baseline BHB and sotagliflozin use. Age, insulin pump use, sotagliflozin use, baseline BHB, and ΔBHB were significantly associated with DKA episodes. Independent of treatment, DKA risk increased by 18% with each 0.1-mmol/L increase in baseline BHB and by 8% with each 0.1-mmol/L increase from baseline | ||
| 520 | |a CONCLUSION: Incremental increases in baseline BHB and ΔBHB were associated with higher DKA risk independent of treatment. Adding sotagliflozin to insulin increased median BHB over 24 weeks in patients with T1D and was associated with increased DKA events. These results highlight the importance of BHB testing and monitoring and individualizing patient education on DKA risk, mitigation, identification, and treatment | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Davies, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a McGill, Janet B |e verfasserin |4 aut | |
| 700 | 1 | |a Pratley, Richard E |e verfasserin |4 aut | |
| 700 | 1 | |a Girard, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Banks, Phillip |e verfasserin |4 aut | |
| 700 | 1 | |a Pettus, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Satish K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes technology & therapeutics |d 1999 |g (2024) vom: 05. März |w (DE-627)NLM113690495 |x 1557-8593 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/dia.2023.0605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 03 | ||